No results were found for your search. Please adjust your search term or broaden your search criteria.
Still can't find what you are looking for? We can prepare Custom Research for you.
Giardiasis is a gastrointestinal infection caused by the protozoan parasite Giardia lamblia. Treatment of giardiasis typically involves the use of antiparasitic drugs, such as metronidazole, tinidazole, and nitazoxanide. These drugs are used to kill the Giardia parasites and reduce symptoms of the infection. In addition, antibiotics may be prescribed to treat any secondary bacterial infections.
The Giardiasis Drug market is a subset of the Gastrointestinal Drugs market, which includes drugs used to treat a variety of gastrointestinal disorders. This market is driven by the increasing prevalence of gastrointestinal diseases, such as irritable bowel syndrome, Crohn's disease, and ulcerative colitis. In addition, the rising demand for effective treatments for giardiasis is expected to drive the Giardiasis Drug market.
Some of the major companies in the Giardiasis Drug market include Merck & Co., Inc., Pfizer Inc., GlaxoSmithKline plc, Sanofi S.A., and Bayer AG. Show Less Read more
